Aspire Private Capital’s Scinai Immunotherapeutics SCNI Stock Holding History

Aspire Private Capital’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3	Closed	-$110	–	539
2024 Q3	$110	Hold	3	–	–	﹤0.01%	654
2024 Q2	$89	Buy	3 +1	+50%	+$41	﹤0.01%	671
2024 Q1	$83	Hold	2	–	–	﹤0.01%	703
2023 Q4	$95	Hold	2	–	–	﹤0.01%	685
2023 Q3	$139	Hold	2	–	–	﹤0.01%	680
2023 Q2	$226	Hold	2	–	–	﹤0.01%	643
2023 Q1	$346	Hold	2	–	–	﹤0.01%	611
2022 Q4	$474	Hold	2	–	–	﹤0.01%	600
2022 Q3	$1K	Hold	2	–	–	﹤0.01%	586
2022 Q2	$2K	Buy	2 +1	+100%	+$1.37K	﹤0.01%	507
2022 Q1	$1K	Buy	+1	New	+$1.45K	﹤0.01%	562

Other funds holding SCNI

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $49.3B AUM 36.45% 1-Year Est. Return

Aspire Private Capital's SCNI Position: Q4 2024 in Review

Aspire Private Capital sold out of Scinai Immunotherapeutics (SCNI) in Q4 2024, closing a stake of 3 shares — an estimated $110 sold.

Aspire Private Capital first reported a position in SCNI in Q1 2022 and held it in 11 quarters. The position peaked at $2K in Q2 2022. 4 funds tracked by Wall St. Rank hold SCNI as of Q4 2024.

Aspire Private Capital reported no remaining Scinai Immunotherapeutics position as of Q4 2024 after selling out during the quarter.
Aspire Private Capital sold 3 Scinai Immunotherapeutics shares in Q4 2024, an estimated $110.
Aspire Private Capital first reported a position in Scinai Immunotherapeutics in Q1 2022 and held it in 11 quarters.
Aspire Private Capital's Scinai Immunotherapeutics position peaked at $2K in Q2 2022.
4 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2024.

Based on Aspire Private Capital's 13F filing for Q4 2024, filed 17 Jan 2025.